Selective glucocorticoid receptor modifiers for treating impaired skin wound healing

An in vitro method for identifying a subject suffering from impaired skin wound healing who is responsive to treatment with a Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, the method comprising:

• i) measuring the proliferation of fibroblast cells, and optionally the amount of at least one IL-1 cytokine marker in the supernatant of fibroblast cells, in the presence of:
• (1) a wound exudate sample or wound biofilm sample obtained from the skin wound of said subject, and
• (2) at least one Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof;
• and/or
• ii) measuring fibroblast-derived matrix formation by fibroblast cells in the presence of:
• (1) a wound exudate sample or wound biofilm sample obtained from the skin wound of said subject, and
• (2) at least one Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof;
• wherein the subject is identified as being responsive to the treatment with a Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, when the value of proliferation of fibroblast cells measured in step i) and/or the value of the fibroblast-derived matrix formation by fibroblast cells measured in step ii) is at least 20% above a control value established in the absence of the at least one Selective Glucocorticoid Receptor Modulator (SEGRM), or pharmaceutically acceptable salt thereof of (2) and, optionally, when the value for the amount of the at least one IL-1 cytokine marker in the supernatant of fibroblast cells obtained in step i) is below a control value established in the absence of the at least one Selective Glucocorticoid Receptor Modulator (SEGRM), or pharmaceutically acceptable salt thereof of (2).

A kit, comprising:

• (a) a pharmaceutical composition comprising at least one Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, and
• (b) one or more of the following:
• i) fibroblast cells,
• ii) a support having a plurality of defined areas or cavities, wherein a subset of areas or cavities are (i) coated with adhesion enhancing agent, and/or (ii) are filled with fibroblast-derived matrix (FDM), and
• iii) a matrix promoting supplement.